| Stage | XYL | % of rev | IEX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $2.2B | 100.00% | $952M | 100.00% | XYL ×2.31 |
| Gross profit | $907M | 41.21% | $430M | 45.13% | IEX +3.9pp |
| Operating income | $385M | 17.49% | $208M | 21.86% | IEX +4.4pp |
| Pre-tax income | $365M | 16.58% | $193M | 20.25% | IEX +3.7pp |
| Net income | $288M | 13.08% | $144M | 15.13% | IEX +2.0pp |
| Stage | XYL | IEX | Gap · A − B |
|---|---|---|---|
| Revenue | $2.2B100.00% | $952M100.00% | XYL ×2.31 |
| Gross profit | 41.21%$907M | 45.13%$430M | IEX +3.9pp |
| Operating income | 17.49%$385M | 21.86%$208M | IEX +4.4pp |
| Pre-tax income | 16.58%$365M | 20.25%$193M | IEX +3.7pp |
| Net income |
| 13.08%$288M |
| 15.13%$144M |
| IEX +2.0pp |
No disclosed counterparties: XYL, IEX.